RxDoctor Payments Data

Eduardo Hernandez, MD

Interventional Cardiology · Houston, TXNPI 1194748004

Payments from drug & device makers

$112,048in general payments, 2019–2025

Across 607 payments — averaging $184.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$68K
  • Amarin Pharma, Inc.$19K
  • Amgen$14K
  • Cardiovascular Systems Inc.$3K
  • Novartis$1K
  • Novo Nordisk$750
  • plus $6K from 44 others

What the payments were for

  • Speaking & faculty fees$97,50587%
  • Travel & lodging$1,6101%
  • Food & beverage$12,82611%
  • Education$1070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$112,048 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$159,212
Medicare patients
325
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$157,223
XareltoRivaroxaban70$91,948
EntrestoSacubitril/Valsartan59$84,873
FarxigaDapagliflozin Propanediol56$69,262
JardianceEmpagliflozin58$59,821
Repatha SureclickEvolocumab77$59,711
VascepaIcosapent Ethyl68$52,454
Praluent PenAlirocumab46$42,015
WegovySemaglutide18$28,664
LivaloPitavastatin Calcium28$25,713
Repatha PushtronexEvolocumab21$20,754
Icosapent Ethyl62$18,787
NexlizetBempedoic Acid/Ezetimibe27$17,827
EdarbyclorAzilsartan Med/Chlorthalidone29$15,076
Nebivolol Hcl202$12,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$557$157,223111 claims
Johnson & JohnsonXarelto$68,314$91,94870 claims
NovartisEntresto$1,150$84,87359 claims
AstraZenecaFarxiga$47$69,26256 claims
Boehringer IngelheimJardiance$126$59,82158 claims
Novo NordiskWegovy$750$28,66418 claims
Kowa Pharmaceuticals America, Inc.Livalo$525$25,71328 claims
Esperion Therapeutics, Inc.Nexlizet$207$17,82727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →